TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the November 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the October 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the September 2025 Update
Category: Pediatrics
-
The March 2024 revision to TAG’s listing includes 26 updates. The annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver from March 3-6, and the addition of links to results from HIV cure-related studies presented at the meeting typically makes this the busiest month for changes — hence the delay to this…
-
No new HIV cure-related trials or studies have been added to the clinicaltrials.gov registry over the past month. Two trials in the listing have changed status: A study sponsored by the ANRS in France investigating the link between specific immune system genetics (MHC B35/53Bw4TTC2) and post-treatment control of HIV is now open for enrollment. Participants…
-
The April 2023 update to TAG’s HIV cure-related clinical research listing adds five new studies, two involving interventions and three observational. Researchers at the University of Sao Paulo General Hospital in Brazil are opening a study of a therapeutic HIV vaccine based on dendritic cells (DCs). DCs are immune system cells tasked with initiating the…
-
Important news has unfolded this week regarding possible additional cases of HIV cures and remission. Yesterday, the London Patient (LP) courageously publicly identified himself as Adam Castillejo in an excellent, thoughtful and empathetic article in the New York Times by Apoorva Mandivilli. While his name is now known, I’ll follow his preference to go by…
-
A new example of long-term post-treatment control of HIV viral load was reported this past Monday at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, attracting widespread media attention. Presented by Asier Sáez-Cirión from Institut Pasteur in France, the case involves a teenager who acquired HIV infection perinatally and was…
-
On November 3rd, the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) announced the launch of the IMPAACT P1115 trial, which will investigate very early initiation of HIV treatment in newborns. Much of the impetus for the trial came from the Mississippi…
-
Initial results from the Canadian pediatric HIV research mentioned in a recent blog post were published in Clinical Infectious Diseases on June 9th. The paper notes that Canada’s three pediatric HIV care institutions have a longstanding policy of administering triple drug antiretroviral therapy (ART) regimens to newborns considered at a high risk of HIV infection (either…
-
Understandably, there has been extensive media coverage of yesterday’s announcement that HIV has rebounded in the “Mississippi Baby” case. Although a full discussion of the implications will take time, there are some points that I think may be worth noting now: The number of individuals considered cured of HIV infection has dwindled back to one:…
-
A news release issued today by the National Institute of Allergy and Infectious Diseases (NIAID) reports the disappointing news that viral load has rebounded in the child in Mississippi who had been considered possibly cured of HIV infection. The child is now nearly four years of age and HIV had remained undetectable without treatment for…
-
An open access paper published in the Journal of Infectious Diseases reports that earlier HIV suppression by ART is associated with significantly smaller HIV reservoirs in perinatally infected youths. The study, by Katherine Luzuriaga and colleagues, was initially presented at CROI last year and compared two groups of four individuals: one group started ART at…